Esterification prolongs retention of budesonide but not ciclesonide - active principle in rat trachea

K. Lexmüller, A. Smailagic, H. Falk Nilsson, M. Lindahl, D. Silberstein, A. Miller-Larsson (Lund, Sweden)

Source: Annual Congress 2005 - Current and emerging anti-inflammatory therapies
Session: Current and emerging anti-inflammatory therapies
Session type: Thematic Poster Session
Number: 2386
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
K. Lexmüller, A. Smailagic, H. Falk Nilsson, M. Lindahl, D. Silberstein, A. Miller-Larsson (Lund, Sweden). Esterification prolongs retention of budesonide but not ciclesonide - active principle in rat trachea. Eur Respir J 2005; 26: Suppl. 49, 2386

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Tissue retention and esterification is greater for budesonide than for ciclesonide in trachea ex vivo
Source: Eur Respir J 2004; 24: Suppl. 48, 345s
Year: 2004

Budesonide is retained in the airways longer than mometasone furoate due to the reversible formation of lipophilic budesonide fatty acid esters - significance for asthma therapy
Source: Eur Respir J 2002; 20: Suppl. 38, 53s
Year: 2002

Relationship between the inhaled and pulmonary absorbed dose of budesonide and mometasone furoate: A study in the isolated perfused rat lung
Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II
Year: 2010

Budesonide is better retained in airway tissue than fluticasone propionate and mometasone furoate due to the formation of lipophilic, slowly hydrolyzed budesonide esters
Source: Eur Respir J 2003; 22: Suppl. 45, 281s
Year: 2003

Greater esterification and retention of budesonide in the airways and lung as compared to ciclesonide after repeated intratracheal administration in vivo
Source: Eur Respir J 2004; 24: Suppl. 48, 345s
Year: 2004

In vitro metabolism of ciclesonide, beclomethasone dipropionate, budesonide and fluticasone propionate in human precision-cut lung slices
Source: Eur Respir J 2005; 26: Suppl. 49, 255s
Year: 2005

Prolonged activity where it matters - the reversible esterfication of budesonide improves its topical anti-inflammatory efficacy and selectivity in the airways
Source: Eur Respir J 2001; 18: Suppl. 33, 21s
Year: 2001

Budesonide prevents cytokine-induced decrease of the relaxant response to formoterol but not to salmeterol in mouse trachea
Source: Annual Congress 2009 - Translational research/biomarkers
Year: 2009


Comparison of inhaled ciclesonide, fluticasone propinate and fluticasone propionate + salmeterol in maintaining asthma control
Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues
Year: 2009

Laninamivir’s prolonged intrapulmonary retention: Intrapulmonary pharmacokinetics (PK) and the intracellular disposition to support the long-lasting efficacy after an inhaled administration of its prodrug laninamivir octanoate (LO)
Source: Annual Congress 2013 –Novel pharmacological findings in the management of respiratory disorders
Year: 2013


Effect of fluticasone propionate (FP)/salmeterol 100/50mcg or FP 250mcg on small airway function
Source: Eur Respir J 2003; 22: Suppl. 45, 260s
Year: 2003

The combination of budesonide and formoterol exerts more rapid and enhanced anti-inflammatory effects than either drug alone in rat lungs in vivo
Source: Eur Respir J 2004; 24: Suppl. 48, 344s
Year: 2004

Late Breaking Abstract - Dose responses for topical efficacy and systemic activity, dose equivalence and relative therapeutic index for fluticasone furoate (FF), fluticasone propionate (FP) and budesonide (BUD) in asthmatic subjects.
Source: International Congress 2019 – New towards old therapies in airway diseases
Year: 2019



Inhibition of allergen-iduced late asthmatic reaction by montelukast versus fluticasone propionate
Source: Eur Respir J 2003; 22: Suppl. 45, 349s
Year: 2003

Beclomethasone, formoterol and glycopyrronium: synergism of triple therapy on human airways
Source: International Congress 2019 – Advances in COPD pharmacology
Year: 2019

Timecourse of action of two inhaled corticosteroids, fluticasone propionate and budesonide
Source: Eur Respir J 2002; 20: Suppl. 38, 308s
Year: 2002

Synergistic interaction between beclomethasone diproprionate and formoterol fumarate in an ex vivo model of bronchial asthma
Source: International Congress 2018 – Basic pharmacology
Year: 2018

High doses of inhaled fluticasone propionate dose-dependently suppress adrenal cortical function in asthmatic children
Source: Eur Respir J 2001; 18: Suppl. 33, 290s
Year: 2001

Effect of addition of salmeterol vs doubling the dose of fluticasone propionate on specific airway resistance in children with asthma
Source: Annual Congress 2008 - Drug therapy and assessment of control in childhood asthma
Year: 2008


Urinary pharmacokinetic method to identify the relative bioavailability of beclometasone dipropionate (BDP) to the lung and body following inhalation
Source: Annual Congress 2010 - Drug delivery and pharmacokinetics I
Year: 2010